Newsroom

Sorted by: Latest

-

AGI Third Quarter 2026 Results Release Date and Conference Call

WINNIPEG, Manitoba--(BUSINESS WIRE)--Ag Growth International Inc. (TSX: AFN) (“AGI”, the “Company”, “we” or “our”) will hold a conference call on Thursday, November 12, 2026, at 8:00am ET to discuss its results for the three-months ending September 30, 2026. A news release announcing AGI’s results will be issued after markets close on Wednesday, November 11, 2026. To attend the event, please join using the AGI Third Quarter Results webcast link. Alternatively, participants can dial-in using +1-...
-

PAG Stock Alert: Halper Sadeh LLC is Investigating Whether Penske Automotive Group, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Penske Automotive Group, Inc. (NYSE: PAG) to Penske Corporation and Mitsui & Co., Ltd. for $212.00 per share in cash.Halper Sadeh encourages Penske shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Penske and...
-

Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced that the first patient who received two infusions, each at 5 × 10⁶ EB103 T cells/kg, three weeks apart, in the dose-expansion phase has tolerated the study drug well in the first month, with no treatment-related serious advers...
-

CORRECTING and REPLACING Voya Equity Closed End Funds Declare Distributions

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Two numbers in the first table of the original version of this release contained erroneous numbers ("$0.065" and "$0.055"), which have been fixed to "$0.085" and "$0.100". The updated release reads: VOYA EQUITY CLOSED END FUNDS DECLARE DISTRIBUTIONS Voya Investment Management, the asset management business of Voya Financial, Inc. (NYSE: VOYA), announced today the distributions on the common shares of three of its closed-end funds: Voya Global Advantage and Pr...
-

إطلاق eM Client 11: بديل قوي لـ Outlook مع حرية الذكاء الاصطناعي وإنتاجية الجيل التالي

براغ--(BUSINESS WIRE)--اليوم، أعلنت شركة eM Client، مطورة تطبيق البريد الإلكتروني والإنتاجية الذي يستخدمه الملايين حول العالم، عن eM Client 11، وهو أهم إصداراتها حتى الآن. بفضل الجمع بين قدرات الذكاء الاصطناعي القوية، والتحسينات الواسعة في الإنتاجية، والتوافق الواسع مع البريد الإلكتروني، يقدم الإصدار الجديد بديلاً عصريًا ومستقلاً لبرنامج Microsoft Outlook.يتناول هذا البيان الصحفي الوسائط المتعددة. يمكنك الاطلاع على البيان كاملاً هنا: https://www.businesswire.com/news/home/20261014043102/ar/الناف...
-

Lanzamiento de eM Client 11: una potente alternativa a Outlook con libertad en IA y productividad de última generación

PRAGA--(BUSINESS WIRE)--eM Client, el desarrollador de una aplicación de correo electrónico y productividad que utilizan millones de personas en todo el mundo, anunció hoy el lanzamiento de eM Client 11, su versión más importante hasta la fecha. Al combinar potentes capacidades de IA, amplias mejoras en la productividad y una gran compatibilidad con el correo electrónico, la nueva versión ofrece una alternativa moderna e independiente a Microsoft Outlook. Productividad impulsada por IA independ...
-

Samenvatting: Takeda presenteert tijdens ESID 2026 de resultaten van de fase 2/3-studie IgGNITE naar het experimentele subcutane geneesmiddel TAK-881 bij primaire immuundeficiëntie (PID)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) maakt gedetailleerde resultaten bekend van de cruciale fase 2/3-klinische studie IgGNITE (TAK-881-3001) waarin het onderzoeksgeneesmiddel TAK-881 [subcutaan toegediend immunoglobuline (humaan), 20%-oplossing (SCIG 20%) en recombinant humaan hyaluronidase] wordt geëvalueerd. Indien goedgekeurd, zou dit de eerste SCIG 20%-behandeling met vereenvoudigde toediening kunnen worden voor patiënten met primaire immuundeficiënti...
-

Future Health lança desafio mundial para impulsionar a inovação em saúde direcionada à aplicação prática

ABU DHABI, EAU--(BUSINESS WIRE)--Future Health – Uma Iniciativa de Abu Dhabi, abriu inscrições para o Desafio de Inovação Digital da Future Health 2026, convidando inovadores de todo o mundo a desenvolver soluções de IA, software e tecnologia conectada que possam ajudar pessoas e sistemas de saúde a compreender as necessidades de saúde com antecedência e agir com maior rapidez. As equipes selecionadas terão acesso a conhecimento técnico e clínico especializado em todo o ecossistema de saúde e i...
-

KBRA Assigns Preliminary Ratings to Sequoia Mortgage Trust 2026-S1 (SEMT 2026-S1)

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to 60 classes of mortgage pass-through certificates from Sequoia Mortgage Trust 2026-S1 (SEMT 2026-S1), a prime RMBS transaction collateralized by 699 mostly seasoned fixed-rate residential mortgage loans with an aggregate scheduled principal balance of approximately $341.7 million. 100% of the pool has been designated as a Qualified Mortgage (QM). KBRA’s rating approach incorporated loan-level analysis of the mortgage pool through its...
-

Future Health startet globalen Wettbewerb, um Gesundheitsinnovationen in die Praxis zu bringen

ABU DHABI, Vereinigte Arabische Emirate--(BUSINESS WIRE)--„Future Health – A Global Initiative by Abu Dhabi“ hat die Bewerbungsphase für die Future Health Digital Innovation Challenge 2026 eröffnet und lädt Innovatoren aus aller Welt ein, Lösungen in den Bereichen KI, Software und vernetzte Technologien zu entwickeln, die Menschen und Gesundheitssystemen helfen, Gesundheitsbedürfnisse früher zu erkennen und schneller zu handeln. Ausgewählte Teams erhalten Zugang zu technischem und klinischem Fa...